VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, December 29, 2025
Stock Comparison
The Estee Lauder Companies Inc. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
The Estee Lauder Companies Inc.
EL · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into The Estee Lauder Companies Inc.'s moat claims, evidence, and risks.
View EL analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 70 / 100 for The Estee Lauder Companies Inc.).
- Segment focus: The Estee Lauder Companies Inc. has 5 segments (48.6% in Skin Care); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: The Estee Lauder Companies Inc. has 4 moat types across 2 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
The Estee Lauder Companies Inc.
Skin Care
Prestige skin care products
Global
Consumers
Branded manufacturer/marketer
48.6%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
The Estee Lauder Companies Inc. strengths
Novo Nordisk A/S strengths
Segment mix
The Estee Lauder Companies Inc. segments
Full profile >Skin Care
Oligopoly
Makeup
Oligopoly
Fragrance
Oligopoly
Hair Care
Competitive
Other
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.